-25% sur tout – jusqu’au 31 octobreLivraison gratuite dès $99 d’achat
SwissChems

Utilisation : Ce produit est destiné uniquement à la recherche.

Toutes les informations sur les produits présentes sur ce site sont fournies à titre éducatif uniquement. Toute forme d’introduction dans le corps humain ou animal est strictement interdite par la loi. Ce produit doit être manipulé uniquement par des professionnels agréés et qualifiés. Il ne s’agit pas d’un médicament, d’un aliment ou d’un cosmétique et il ne doit pas être présenté, utilisé ou étiqueté comme tel.

Ipamorelin 2mg

Même formule de confiance. Nouveau look.

Pendant notre changement d’emballage, vous pouvez recevoir des produits avec l’ancienne ou la nouvelle étiquette. La formulation, la pureté et la qualité restent exactement les mêmes, selon nos standards.

Moyens de paiement acceptés
  • Carte de crédit
  • Virement bancaire (SEPA instantané)
  • Virement bancaire (ACH)
  • Wise
  • Revolut
  • Zelle
  • Remitly
  • Western Union
  • Chime
  • Autres

-25% sur tout – jusqu’au 31 octobre
25% sur les prix habituels, en remplacement des autres soldes. Cumulable uniquement avec la remise crypto.

Livraison

Expédition le jour même pour les commandes aux États-Unis passées avant 12 h EST.

Voir la politique de livraison →
Retours

Retours faciles sous 30 jours pour les produits non ouverts.

Voir la politique de retour →
Testé en laboratoire

Chaque lot est testé pour sa pureté, sa puissance et sa qualité.

Voir les résultats d’analyse →
Assistance

Une question ? Écrivez-nous sur Telegram.

Ouvrir le chat →

Ipamorelin is a synthetic pentapeptide and highly selective agonist of the growth hormone secretagogue receptor subtype 1a (GHS-R1a). The compound is characterized by strong receptor selectivity and a well-defined pharmacological profile, making it a useful tool for investigating GHS-R1a-mediated signal transduction and ligand-receptor interactions.

Research applications include GHS-R1a pharmacology, receptor activation kinetics, signaling pathway characterization, structure-activity relationship investigations, and comparative analyses of growth hormone secretagogue receptor ligands.

  • High Purity – 99% Purity Guaranteed
  • Independently Lab Tested
  • Research Grade Quality
  • For Laboratory Research Use Only

3D Molecular Structure

Drag to rotate · scroll to zoom
Loading 3D structure…
Ipamorelin-2mg1 vial | KIT (10 vials)
Chemical Formula C38H49N9O5
Synonyms 2-Methylalanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide, 170851-70-4, C38H49N9O5, CHEMBL58547, SCHEMBL183305, SCHEMBL8169698, MolPort-039-139-953, 5020AF, ZINC29562299, AKOS030573449, DB12370, NCGC00167295-01, FT-0696037
Molar Mass 711.9 g/mol
CAS Number 170851-70-4
PubChem CID 9831659
Total Compound Content 2 mg per vial
Shelf Life 36 months
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) and highly selective agonist of the growth hormone secretagogue receptor subtype 1a (GHS-R1a). Its defining pharmacological characteristic is a high degree of receptor selectivity relative to earlier growth hormone secretagogue receptor ligands, making it a valuable tool for investigating GHS-R1a-mediated signaling pathways and ligand-receptor interactions. Activation of GHS-R1a by Ipamorelin initiates Gq/11-coupled phospholipase C signaling, resulting in IP3 and DAG second-messenger generation, intracellular calcium mobilization, and downstream signal transduction events. Pharmacokinetic investigations have characterized the compound's receptor engagement profile and elimination dynamics in experimental systems. Research applications include GHS-R1a pharmacology, receptor activation kinetics, signal transduction characterization, structure-activity relationship investigations, and comparative analyses of selective growth hormone secretagogue receptor ligands. Supplied as a lyophilized preparation (2 mg/vial). Independently third-party HPLC-tested; COA available per batch.

Results refer to the tested sample. Check the batch and date in the report.

Ipamorelin (2605-ED-IP)
September 13, 2026
Ipamorelin (2607-ED-IP)
September 13, 2026
Ipamorelin (2608-CY-IP)
September 13, 2026
Ipamorelin (AY0811-IP2)
September 4, 2026
Ipamorelin (2606CYIP)
August 26, 2026
Ipamorelin (ED9630)
June 16, 2026
What makes Ipamorelin more selective than other GHS-R1a agonists?

Ipamorelin is characterized by a highly selective interaction with GHS-R1a and a well-defined pharmacological profile relative to earlier growth hormone secretagogue receptor ligands. This selectivity makes it a valuable research tool for investigating GHS-R1a-mediated signaling pathways, receptor activation kinetics, and ligand-receptor interactions without the broader receptor activity observed with less selective secretagogues.

What is the pharmacokinetic profile of Ipamorelin?

Pharmacokinetic investigations have reported a relatively short elimination profile compared with longer-acting GHS-R1a agonists. This characteristic makes Ipamorelin useful for studies examining receptor engagement dynamics, activation kinetics, signal transduction timing, and the temporal aspects of GHS-R1a-mediated signaling.

How does Ipamorelin compare with GHRH analogues in receptor pharmacology research?

Ipamorelin and GHRH analogues interact with distinct receptor systems and signaling pathways. Ipamorelin acts through GHS-R1a, whereas compounds such as CJC-1295 and Sermorelin target the growth hormone-releasing hormone receptor (GHRHR). Comparative investigations utilize these compounds to examine differences in receptor activation mechanisms, downstream signaling architecture, ligand selectivity, and pathway-specific signal transduction.